• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

再利用 FDA 批准的药物治疗阿片类药物使用障碍。

Re-Purposing FDA-Approved Drugs for Opioid Use Disorder.

机构信息

Doctor of Medicine Program, Penn State College of Medicine, Hershey, Pennsylvania, USA.

Departments of Anesthesiology and Perioperative Medicine and Pharmacology, Penn State College of Medicine, Hershey, Pennsylvania, USA.

出版信息

Subst Use Misuse. 2023;58(13):1751-1760. doi: 10.1080/10826084.2023.2247071. Epub 2023 Aug 16.

DOI:10.1080/10826084.2023.2247071
PMID:37584436
Abstract

OBJECTIVE

To investigate FDA-approved drugs prescribed for unrelated diseases or conditions that promote remission in subjects diagnosed with opioid use disorder (OUD).

METHODS

This was a retrospective observational study utilizing the TriNetX electronic medical record data. Subjects between 18 and 65 years old were included in this study. First, a drug screen was employed to identify medications used for chronic illness that are associated with OUD remission. Based on Fisher's exact test for significance, 28 of 101 medications were selected for further analysis. Positive (buprenorphine/methadone) and negative controls (benazepril) were included in the analysis. Medications were analyzed in the absence and presence of buprenorphine or methadone, two medications used to treat OUD, to identify the likelihood of OUD remission up to one year following the index event.

RESULTS

We identify 8 medications (prazosin, propranolol, lithium carbonate, olanzapine, quetiapine, bupropion, citalopram, and escitalopram) that may be useful for increasing remission in OUD in the absence of buprenorphine or methadone. Additionally, our results identify psychiatric medications that when taken alongside buprenorphine and methadone improve remission rates.

CONCLUSION

These results provide medication options that may be useful in treating OUD as well as integrated therapies to treat comorbid mental illness.

摘要

目的

调查美国食品和药物管理局 (FDA) 批准用于治疗与阿片类药物使用障碍 (OUD) 无关的疾病或病症的药物,以促进这些患者的缓解。

方法

这是一项回顾性观察性研究,使用了 TriNetX 电子病历数据。本研究纳入了年龄在 18 至 65 岁之间的受试者。首先,进行药物筛选以确定用于治疗与 OUD 缓解相关的慢性疾病的药物。基于 Fisher 确切检验的显著性,从 101 种药物中选择了 28 种进行进一步分析。阳性对照(丁丙诺啡/美沙酮)和阴性对照(贝那普利)纳入了分析。分析了在没有和存在丁丙诺啡或美沙酮(两种用于治疗 OUD 的药物)的情况下的药物,以确定在索引事件发生后一年的时间内 OUD 缓解的可能性。

结果

我们确定了 8 种药物(哌唑嗪、普萘洛尔、碳酸锂、奥氮平、喹硫平、安非他酮、西酞普兰和艾司西酞普兰),在没有丁丙诺啡或美沙酮的情况下,这些药物可能对增加 OUD 的缓解有用。此外,我们的结果还确定了一些精神科药物,当与丁丙诺啡和美沙酮一起使用时,可以提高缓解率。

结论

这些结果提供了一些可能对治疗 OUD 有用的药物选择,以及治疗共病精神疾病的综合治疗方法。

相似文献

1
Re-Purposing FDA-Approved Drugs for Opioid Use Disorder.再利用 FDA 批准的药物治疗阿片类药物使用障碍。
Subst Use Misuse. 2023;58(13):1751-1760. doi: 10.1080/10826084.2023.2247071. Epub 2023 Aug 16.
2
Medications for Maintenance Treatment of Opioid Use Disorder in Adolescents: A Narrative Review and Assessment of Clinical Benefits and Potential Risks.青少年阿片类物质使用障碍维持治疗药物:临床获益和潜在风险的叙述性综述和评估。
J Stud Alcohol Drugs. 2019 Jul;80(4):393-402.
3
Association of Opioid Use Disorder Treatment With Alcohol-Related Acute Events.阿片类药物使用障碍治疗与酒精相关的急性事件的关联。
JAMA Netw Open. 2021 Feb 1;4(2):e210061. doi: 10.1001/jamanetworkopen.2021.0061.
4
Medications for management of opioid use disorder.阿片类药物使用障碍的药物治疗。
Am J Health Syst Pharm. 2019 Jul 18;76(15):1097-1103. doi: 10.1093/ajhp/zxz105.
5
Perceived social support in patients with chronic pain with and without opioid use disorder and role of medication for opioid use disorder.伴有和不伴有阿片类药物使用障碍的慢性疼痛患者的感知社会支持以及阿片类药物使用障碍药物治疗的作用。
Drug Alcohol Depend. 2021 Apr 1;221:108619. doi: 10.1016/j.drugalcdep.2021.108619. Epub 2021 Feb 15.
6
Polysubstance use and association with opioid use disorder treatment in the US Veterans Health Administration.美国退伍军人事务部的多药物使用与阿片类药物使用障碍治疗的关系。
Addiction. 2021 Jan;116(1):96-104. doi: 10.1111/add.15116. Epub 2020 Jul 7.
7
Perceptions of extended-release naltrexone, methadone, and buprenorphine treatments following release from jail.出狱后对纳曲酮、美沙酮和丁丙诺啡延长释放治疗的看法。
Addict Sci Clin Pract. 2019 Oct 1;14(1):37. doi: 10.1186/s13722-019-0166-0.
8
Real-world effectiveness of pharmacological treatments of opioid use disorder in a national cohort.真实世界中全国队列中阿片类药物使用障碍的药物治疗效果。
Addiction. 2022 Jun;117(6):1683-1691. doi: 10.1111/add.15814. Epub 2022 Feb 7.
9
Multimodal assessment of sleep in men and women during treatment for opioid use disorder.男性和女性在治疗阿片类药物使用障碍期间的睡眠多模态评估。
Drug Alcohol Depend. 2020 Feb 1;207:107698. doi: 10.1016/j.drugalcdep.2019.107698. Epub 2019 Nov 18.
10
Long-term follow-up assessment of opioid use outcomes among individuals with comorbid mental disorders and opioid use disorder treated with buprenorphine or methadone in a randomized clinical trial.在一项随机临床试验中,对接受丁丙诺啡或美沙酮治疗的共患精神障碍和阿片类药物使用障碍个体的阿片类药物使用结果进行长期随访评估。
Addiction. 2022 Jan;117(1):151-161. doi: 10.1111/add.15594. Epub 2021 Jun 22.

引用本文的文献

1
A comprehensive review of methodologies and application to use the real-world data and analytics platform TriNetX.对使用真实世界数据和分析平台TriNetX的方法及其应用的全面综述。
Front Pharmacol. 2025 Mar 10;16:1516126. doi: 10.3389/fphar.2025.1516126. eCollection 2025.
2
A Narrative Review of Old and Emerging Treatment Modalities for Substance Use Disorders.物质使用障碍的传统与新兴治疗方式叙事综述
Cureus. 2024 Dec 9;16(12):e75395. doi: 10.7759/cureus.75395. eCollection 2024 Dec.
3
Unlocking New Potential: Drug Repurposing and Innovative Pharmaceutics.
释放新潜力:药物再利用与创新制药学。
Curr Drug Res Rev. 2025;17(2):127-131. doi: 10.2174/0125899775282901240130113010.